Crispr Therapeutics: Betting On A One-Shot Future

Core Insights - The article discusses Crispr Therapeutics AG's diversified gene-editing pipeline and highlights a strong cash position of $2.1 billion, which supports its ongoing projects [1]. Group 1 - The company has a diversified gene-editing pipeline that is crucial for its growth and innovation in the biotech sector [1]. - The strong cash position of $2.1 billion provides a solid financial foundation for the company's research and development efforts [1].